Del Campo Milan Marta, Zuroff Leah, Jimenez Connie R, Scheltens Philip, Teunissen Charlotte E
Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands; Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.
OncoProteomics Laboratory, Department Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Alzheimers Dement (Amst). 2015 Mar 29;1(1):75-80. doi: 10.1016/j.dadm.2014.11.008. eCollection 2015 Mar.
The need for effective treatments halting Alzheimer's disease (AD) urges the discovery of the earliest possible biomarkers. Agrin is increased in the early stages of AD and is involved in amyloid-β (Aβ) fibrillation and synaptogenesis. We investigated the potential of agrin as an early AD cerebrospinal fluid (CSF) biomarker. We analyzed the agrin CSF concentration in nondemented controls (n = 20) and those with mild (n = 20) and severe (n = 20) AD. The levels of agrin CSF were not significantly divergent among the different patient groups and did not correlate with the concentration of Aβ42, total tau, phosphorylated tau, or the Mini Mental State Examination scores. However, agrin strongly correlated with age in those with dementia. The results indicate that agrin cannot be used as an early AD CSF biomarker using the current immunoassay. However, our population was relatively young; thus, the correlation between agrin and age suggests that stronger differences in agrin concentrations might be found in older groups with more heterogeneous AD pathologic features.
对有效治疗阿尔茨海默病（AD）的需求促使人们尽早发现生物标志物。聚集蛋白在AD早期会增加，并参与β淀粉样蛋白（Aβ）的纤维化和突触形成。我们研究了聚集蛋白作为早期AD脑脊液（CSF）生物标志物的潜力。我们分析了非痴呆对照者（n = 20）、轻度AD患者（n = 20）和重度AD患者（n = 20）脑脊液中聚集蛋白的浓度。不同患者组之间聚集蛋白脑脊液水平没有显著差异，且与Aβ42、总tau蛋白、磷酸化tau蛋白的浓度或简易精神状态检查表评分均无相关性。然而，在痴呆患者中，聚集蛋白与年龄密切相关。结果表明，使用当前的免疫测定方法，聚集蛋白不能用作早期AD脑脊液生物标志物。然而，我们的研究人群相对年轻；因此，聚集蛋白与年龄之间的相关性表明，在具有更多异质性AD病理特征的老年人群中，可能会发现聚集蛋白浓度存在更大差异。
